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Summary. Background: Limited data exist on the clinical
manifestations of homozygous factor (F)V:G1691A mutation
(FV Leiden) and the impact of environmental and genetic risk
factors. Objectives: To assess the contribution of these factors
on the thrombophilic phenotype. Patients and methods: In a
retrospective multicenter cohort study 165 individuals with
homozygousFV:G1691Amutation, of whom129 had previous
venous thromboembolism (VTE), were included. To study the
role of environmental risk factors, patients were compared by
the use of a standardized questionnaire to 165 sex- and age-
matched individuals (reference group A); of these, two had
previous VTE. To assess the role of genetic risk factors, factor
(F)II:G20210A and MTHFR:C677T were determined in
individuals homozygous for FV:G1691A and in 177 healthy
individuals without previous VTE (reference group B).
Results: The ﬁrst VTE occurred signiﬁcantly earlier in women
(median age 25 years) thanmen (35.5 years). In 81%ofwomen
and 29% of men an environmental risk factor was present
before ﬁrst VTE. Oral contraceptives increased the risk of
thrombosis 4-fold [odds ratio (OR) 4.0, 95%conﬁdence interval
(CI) 1.7, 10.4] in women with homozygous FV:G1691A.
Postoperative and post-traumatic VTE as ﬁrst manifestation
occurred in 13% and 15% of surgical/traumatic events in
patients and in 0.7% and 1.8% in reference group A,
respectively (OR 19.7, 95% CI 2.5, 154 and OR 9.2, 95% CI
1.1, 79.4). Heterozygous FII:G20210A was more prevalent in
symptomatic patients (11.7%) compared with reference group
B (2.8%, OR 4.6, 95% CI 1.6, 13.2). The prevalence of
homozygousMTHFR:C677T genotype was similar in patients
and reference group B. Conclusions: Our study supports the
concept of thrombophilia as a multifactorial disorder. The
knowledge of coexisting factors predisposing to VTE is useful
for medical advice for primary and secondary prophylaxis in
these patients.
Keywords: factor V Leiden, homozygous factor V:G1691A,
oral contraceptives, prothrombin G20210A variation, throm-
bophilia, venous thrombosis.
Introduction
In the last decades genetic defects in proteins regulating blood
coagulation have been established as risk factors predisposing
to venous thromboembolism (VTE). The most important are
antithrombin, protein C and protein S deﬁciency, resistance to
activated protein C due to the factor (F)V G1691A gene
mutation (FV:R506Q, FV Leiden) and the factor (F)II gene
G20210A variant [1–5]. Homozygosity of the C to T substi-
tution at nucleotide 677 within the methylene tetrahydrofolate
reductase gene has been shown to be associated with mild to
moderate hyperhomocysteinemia, which is recognized as a risk
factor for vascular disease [6–17]. However, the contributing
role of homozygous MTHFR:C677T to venous thrombosis
remains unclear [8].
Among the risk factors mentioned, the FV:G1691A muta-
tion has been identiﬁed as the most common with an average
prevalence of 20% in unselected patients with ﬁrst VTE, and
approximately 3–7% in the general Caucasian population
[1,2,9–12]. The prevalence of individuals homozygous for FV
Leiden in the general population is around 1 in 2500 [13]. In a
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previous study the prevalence of homozygous FV:G1691A
carriers was 4.1% among 1200 consecutive patients with a
history of an objectively conﬁrmed juvenile VTE compared
with 0% among 450 healthy controls [14]. Whereas the relative
risk of VTE is moderately increased in heterozygous
FV:G1691A carriers (3–8-fold), it is 30–140-fold increased in
homozygous individuals [4,5,13,14]. Coinheritance of the
FV:G1691A mutation with other genetic defects in the
hemostatic system potentiates the thrombotic risk, as does
the presence of acquired prothrombotic risk factors [15–17].
Although both the thrombotic tendency and importance of
coexistent prothrombotic risk factors have been investigated in
carriers of FV:G1691A, most studies included mainly hetero-
zygotes. This prompted us to analyze the clinical feature in a
large cohort of FV:G1691A homozygotes and to assess how
the concomitant presence of genetic coagulation disorders or
environmental risk factors contributes to the thrombophilic
phenotype observed in these subjects.
Subjects and methods
Five European centers from Austria (Vienna), Germany
(Frankfurt, Cologne, Kaiserslautern) and Hungary (Budapest)
with laboratory and clinical experience in diagnosing and
managing patients with thrombophilia participated in this
study.
Patients
A total of 172 homozygous FV:G1691A outpatients were
registered at the participating centers at the time of the study
and 165 (102 women, 63 men) with a median age of 38.5 years
(range 11–84 years) were enrolled (Table 1). Only three
patients from Frankfurt and four from Vienna could not be
enrolled because of unwillingness to participate. Some of the
patients were also enrolled in the European Prospective Cohort
on Thrombophilia Study (EPCOT). Information on the
thromboembolic disease was obtained from patient documen-
tation ﬁles and personal interview. Follow-up covered the life
time of each study individual.
A questionnaire was completed for each patient during a
visit to the participating center, which emphasized history and
characteristics of thrombotic manifestations, including date of
occurrence, site of every thrombotic episode, and the presence
of precipitating factors (e.g. surgery, trauma, prolonged
immobilization, pregnancy or puerperium, and oral contra-
ceptive intake). Of 165 homozygous carriers, 129 (78 women,
51 men) had a history of at least one VTE prior to their referral
to the thrombosis centers. The vast majority of the sympto-
matic patients was referred for thrombophilia screening. We
used the term VTE for deep vein thrombosis (DVT) and
pulmonary embolism (PE) and also for major thromboembolic
events at unusual sites, but not for superﬁcial thrombophlebitis
(STP). Diagnosis of VTE was made by objective methods,
including ultrasonography, duplex scanning, contrast venog-
raphy, computed tomography (CT) or magnetic resonance
imaging. Diagnosis of PE had been conﬁrmed by the presence
of ventilation-perfusion mismatch on a lung scan and/or CT
and/or the presence of thrombus in the pulmonary vasculature
conﬁrmed by pulmonary angiography or other appropriate
objective methods for thrombosis at unusual sites. Events that
were not objectively conﬁrmed were included, if the clinical
feature was typical and had led to hospitalization and/or
anticoagulant treatment. Thirty-six subjects (24 women, 12
men) were diagnosed during family studies (n ¼ 16) or
screening before prescription of oral contraceptives (OC,
n ¼ 20) and had no history of DVT or PE, while seven had
a history of only STP. The diagnosis of STP was based on
typical clinical symptoms and was conﬁrmed by ultrasonogra-
phy in some cases. None of the homozygous carriers had
antiphospholipid antibody syndrome. The concomitant pres-
ence of a natural inhibitor deﬁciency was identiﬁed in six
symptomatic patients (heterozygous type I deﬁciency of
antithrombin, protein C, and protein S in two cases each).
Reference population
To study the effect of environmental factors on the clinical
manifestation of thrombosis, a reference group (reference
group A) consisting of 165 subjects (102 women, 63 men) from
the normal population of the same geographic region and the
same ethnic background as the patients, who were matched for
sex and age (± 5 years) with the FV Leiden carriers (median
age 39 years, range 12–86 years), was included. Individuals in
this reference group had to be unrelated to the patients, and
were either acquaintances of the patient, or from hospital staff
or friends or relatives of hospital staff. They were evaluated in
the same way as the patients by a questionnaire either by
telephone or direct personal interview. There were no further
exclusion criteria for recruitment of these reference subjects and
Table 1 Characteristics of patients with homozygous factor V:G1691A
Women Men Total
Subjects, n 102 63 165
Median age, years (range) 34.5 (11–75) 48 (15–84) 38.5 (11–84)
Patients with VTE, n (%) 78 (76) 51 (81) 129 (78)
Median age, years (range) 35 (18–75) 48 (18–84) 39 (18–84)
Patients with recurrent VTE, n (%)* 29 (38) 26 (51) 55 (43)
Patients without VTE, n (%) 24 (24) 12 (19) 36 (22)
Median age, years (range) 32.5 (11–65) 41.5 (15–78) 34 (11–78)
*Percent of patients with venous thromboembolism (VTE). Seven patients had a history of superﬁcial thrombophlebitis.
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no laboratory investigations were performed in this group to
exclude thrombophilic defects. Two individuals from this
reference group (both women) had a history of VTE, one a
DVT and the other a PE. A further 13 persons (10 women and
three men) of this group had a history of STP.
To study the effect of OCs among women homozygous for
FV:G1691A, we compared the prevalence of OC use at the
time of thrombosis in the symptomatic women with
FV:G1691A with the prevalence of OC use in the population
reference group A, with the assumption that this prevalence
would estimate fairly the prevalence in asymptomatic and
undiagnosed FV:G1691A carriers. This approach was chosen
because it was not possible to study OC use in a large
asymptomatic group of FV:G1691A carrier women.
To study the impact of major surgical procedures and leg
trauma as precipitating conditions for VTE, we assessed such
risk factors in homozygous carriers, and the frequency of
subsequent thrombosis. We compared the frequency and
distribution of these risk factors in the patients and in reference
group A and included all individuals from reference group A in
this analysis. Only surgical procedures and leg injuries that had
occurred before the ﬁrst VTE were evaluated and therefore a
comparable prophylactic anticoagulation scheme in patients
and controls can be assumed. Only thrombotic events that
occurred in close temporal connection to surgery or trauma
(£ 6 weeks) were regarded as triggered events.
To evaluate the prevalence of the FII:G20210A and the
homozygous MTHFR:C677T variants in the normal popula-
tion a second reference group of 177 individuals (median age
36 years, range 19–84, 57%women) from the same geographic
region and the same ethnic background as the patients, who
had no history of arterial or venous thromboembolic events,
and who were previously diagnosed as carrying the wild-type
FV:G1691A genotype, were investigated (reference group B).
Here we used the same approach as in studying the additional
risk of OCs among homozygous individuals, i.e. we used the
prevalence of prothrombin and MTHFR variant among
healthy controls as a proxy for the prevalence among
homozygous patients without thrombosis. The odds ratio
(OR) estimates the relative risk for these variants among
individuals with homozygous FV:G1691A carriers.
Blood sampling and assays for gene analysis
For genetic analysis EDTA or citrated blood samples were
collected by peripheral venepuncture. DNA was extracted by
standard procedures. Determination of the FII:G20210A,
FV:G1691A, and MTHFR:C677T genotypes by polymerase
chain reaction was done according to published protocols
[4,6,10].
Statistical analysis
Statistical analysis was performed using the Stat View 5.0
program (SAS Institute Inc., Cary, NY, USA). Statistical tests
were based on contingency tables (v2 test and Fischer’s exact
test). In addition, relative risks of VTE were calculated based
on the incidence of events in the various groups, with 95%
conﬁdence intervals (95% CI) based on the assumption of a
Poisson distribution for the number of events. The method of
Kaplan–Meier was used to show graphically the age at
occurrence of VTE. For comparison of men and women the
log rank test was applied.
Ethics
The present multicenter study was performed in accordance
with the ethical standards laid down in the relevant version of
the Declaration of Helsinki. All study subjects gave their
informed consent to perform genetic analysis to test for
mutations associated with an increased risk of thrombosis.
Results
Thromboembolic episodes
Themain characteristics of the study groupare listed inTable 1.
Of the 165 homozygous FV:G1691A carriers, 129 (78.2%, 78/
102 women and 51/63 men) had suffered at least one DVT or
PE, 55of these (29women/26men) had recurrentVTE (42.6%).
Thirty-six homozygous carriers were either completely asymp-
tomatic (n ¼ 29) or had a history of STP only (n ¼ 7).
In Table 2 the characteristics of the ﬁrst VTE are listed. In
most of the 129 symptomatic homozygousFV:G1691A carriers
the ﬁrst thrombotic event was DVT of the leg, associated with
PE in 23%. Unusual manifestations of VTE were documented
in ﬁve patients, while primary PE occurred in one case only. At
the time of the ﬁrst VTE episode, none of the 129 symptomatic
FV:G1691A homozygotes had overt evidence of an underlying
disorder known to be associated with increased risk of VTE,
such as autoimmune, neoplastic or severe cardiac disease. Only
19.2% of women developed the ﬁrst VTE without any known
environmental risk factor, whereas this was the case in 73% of
men (P < 0.0001). Forty-three women developed VTE during
intake of OC, in four of these an additional triggering condition
was present. In Fig. 1 the age at occurrence of VTE in women
and men is shown by using the method of Kaplan–Meier.
WomendevelopedVTEsigniﬁcantlyearlier comparedwithmen
(log rank test P ¼ 0.0001).
Vascular events that occurred in the symptomatic patients
during 5322 patient observation years are listed in Table 3.
Isolated DVT was the most common event. PE was diagnosed
in 46 patients: in seven patients PE occurred as an apparently
isolated event, while in the remaining 39 patients PE was
associated with lower extremity DVT. Superﬁcial thrombo-
phlebitis was reported 293 times in 64 patients, and thus was
more frequent than any other vascular complication.
OC intake as triggering condition for the first VTE in women
To evaluate the inﬂuence of OC intake for risk of VTE in
women homozygous for FV:G1691A, the frequency of OC
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intake in women with FV:G1691A at the time of thrombosis
was compared with the frequency of OC intake in control
women of reference groupAof the same age. Fifty womenwith
homozygous FV:G1691A fulﬁlled the criteria of having had a
thrombosis and having amatched control woman inwhomOC
intake was exactly known. Of the 50 women with homozygous
FV:G1691A and thrombosis 38 took OC (76%), whereas 12
(24%) did not. Of the 50 control women 22 (44%) had OC,
whereas 28 (56%) had not. This indicates that among women
homozygous for FV:G1691A, OCs increase the risk of
thrombosis 4-fold (OR 4.0, 95% CI 1.6, 10.4).
Surgical procedures and leg injury as triggering events for the
first VTE (Table 4)
Thirteen percent of operations (12/95) in patients were compli-
cated by a ﬁrst symptomatic VTE, whereas this was the case in
only 0.7% (1/136) of persons of reference group A (OR 19.7,
95% CI 2.5, 154). Abdominal surgery was followed by VTE in
only 7.3% of procedures, whereas orthopedic and urological
procedures had the highest risk of VTE (20% or higher).
Table 2 Clinical characteristics of ﬁrst venous thromboembolism (VTE) in 129 symptomatic patients with homozygous factor V:G1691A
Women
n ¼ 78
Men
n ¼ 51
Total
n ¼ 129
Site of VTE
DVT without symptomatic PE, n (%)* 53 (68) 41 (80) 94 (73)
DVT + PE, n (%) 20 (26) 9 (18) 29 (23)
Isolated PE, n (%) 1 (1.3) 0 1 (0.8)
Unusual site, n (%) 4 (5.1) 1 (2) 5 (3.9)
Age at ﬁrst manifestation
Age (years), median (range) 25 (0.1–65)§ 35.5 (14–82)§ 29 (0.1–82)
Prothrombotic conditions associated with ﬁrst VTE episode–
None, n (%) 15 (19.2) 37 (73) 51 (39.5)
Major surgery, n (%) 5 (6.4) 8 (15.7) 14 (10.9)
Trauma, n (%) 4 (5.1) 5 (9.8) 9 (7.0)
Immobilization, n (%) 2 (2.6) 3 (5.9) 5 (3.9)
Pregnancy, n (%) 8 (10.3)
Puerperium, n (%) 6 (7.7)
Intake of oral contraceptives, n (%) 42 (54)
DVT, Deep vein thrombosis; PE, pulmonary embolism. *One woman extending into the caval vein. Two men extending into the caval vein. One
man with retinal, one woman with cerebral, renal, jugular and arm vein thrombosis, respectively. §P < 0.0001 difference women vs. men. –Two
men and four women had more than one single risk factor.
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Fig. 1. Probability of development of thrombosis in symptomatic
women (n ¼ 78) and men (n ¼ 51), log rank test, P ¼ 0.0001.
Table 3 Vascular events in 129 symptomatic patients with homozygous
factor V:G1691A during 5322 patient years
Vascular
events
n ¼ 531
Patients*
n ¼ 129
Venous thromboembolic episodes
Deep leg vein thrombosis 165 101
Deep leg vein thrombosis + PE 44 39
Isolated PE 10 7
Deep arm vein thrombosis 9 8
Retinal vein thrombosis 5 3
Renal vein thrombosis 1 1
Cerebral vein thrombosis 3 3
Isolated caval vein thrombosis 1 1
Superﬁcial thrombophlebitis, n 293 64
PE, Pulmonary embolism. *Some of the patients had events at dif-
ferent sites. One female extending into the caval vein. Four patients
extending into the caval vein.
Table 4 Thrombotic complications (deep vein thrombosis and/or pul-
monary embolism) in association with major surgical procedures and
trauma of the leg in homozygous FV:G1691A carriers
Number of procedures/venous
thromboembolism episodes (%)
n ¼ 165
Type of surgery
Abdominal 55/4 (7.3)
Gynecological 10/1 (10)
Orthopedic 17/4 (24)
Urological 7/3 (43)
Thoracic 1/0
Various 5/0
All surgical procedures 95/12 (13)
Trauma of the leg 40/6 (15)
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Leg trauma (fractures or soft-tissue trauma leading to
immobilization) were followed by a ﬁrst VTE in 15% (6/40) of
patients and in 1.8% (1/55) of reference group A (OR 9.2, 95%
CI 1.2, 79.4).
Coinheritance of FII:G20210A and MTHFR:C677T genotypes
To asses the role of FII:G20210A and MTHFR:C677T as
additional risk factors predisposing to thrombosis in
FV:G1691A homozygotes, 111 symptomatic homozygous
FV:G1691A carriers were investigated for these mutations.
To focus on FII:G20210A and MTHFR:C677T as potential
factors contributing to the thrombophilic phenotype in homo-
zygous FV:G1691A carriers, patients with coexisting deﬁcien-
cies of antithrombin, protein C, and protein S (n ¼ 6) were
excluded from this analysis. Data on the prevalence of the
FII:G20210A and MTHFR:C677T mutations are shown in
Table 5.
Among the 111 homozygous FV:G1691A carriers a coex-
istence with the FII:G20210A was detected in 8.9% of the
patients compared with 2.8% in reference group B. This
difference was highly signiﬁcant. No increase in the frequency
of the homozygousMTHFR:C677T genotype was observed in
symptomatic homozygous FV:G1691A carriers comparedwith
reference group B.
Discussion
Only limited data on the clinical features of thrombophilia and
the contribution of circumstantial and/or genetic risk factors
are available for homozygotes [17–22]. Therefore, we present
the results of a multicenter study on the thrombophilic
phenotype and the concurrent effects of additional prothrom-
botic risk factors in a large cohort of homozygous FV:G1691A
carriers.
In women with the homozygous FV:G1691A mutation the
ﬁrst VTE occurred approximately 10 years earlier compared
with men. This difference is most probably due to the increased
risk of thrombosis in homozygous women associated with OC
[23] and pregnancy [24]. A higher prevalence of environmental
prothrombotic risk factors at ﬁrst thrombotic manifestation
was present in women compared with men. OC and pregnancy
were the most frequent additional risk factors in women. For
thrombosis during OC use an OR of 4.0 was found. This is
similar to the VTE risk of OC known from case–control studies
[25] and this increased risk is superimposed on the increased
basic risk of VTE in homozygous FV Leiden patients. These
data conﬁrm the previous assumption that subjects with
homozygous FV:G1691A are particularly predisposed to VTE
while using OC [21–23]. Due to this high risk, OCs containing
ethinylestradiol should not be prescribed to women known to
be homozygous for FV:G1691A mutation.
DVT without and with PE was the most prevalent major
thrombotic manifestation. STP was more frequently reported
than any other event. STP is a less severe manifestation within
the phenotypic spectrum of venous thrombophilia, and is
therefore often disregarded by physicians. In patients with
idiopathic STP Martinelli et al. reported an OR of 6.1 for the
FV:G1691A mutation, 4.3 for the FII:G20210A genotype and
12.9 for deﬁciencies of a natural coagulation inhibitor [26]. The
early recognition and treatment of STP is important, because
progression of thrombosis into the deep venous system may
occur in a high proportion of cases [27–29].
To investigate further the interactions between genetic and
environmental factors we evaluated the prevalence of a ﬁrst
VTE after surgery and trauma in patients with homozygous
FV:G1691A and controls from reference group A. The overall
prevalence was considerably higher in patients than in controls.
Furthermore, 15% of leg injuries documented in FV:G1691A
carriers were followed by VTE episodes, which was almost 10-
fold higher than in the control group. Thus, bothmajor surgery
and leg trauma were associated with a signiﬁcantly increased
risk of VTE in homozygous FV:G1691A patients. In patients
with known homozygous FV:G1691A, antithrombotic pro-
phylaxis should be recommended at the time of both condi-
tions. However, due to the low prevalence of the homozygous
FV:G1691A genotype in the normal population, general
preoperative screening seems not to be reasonable.
As one of the most marked ﬁndings of our study we
observed that the prevalence of the FII:G20210A variation was
higher among homozygous FV:G1691A carriers with a history
of VTE compared with the group of healthy individuals. This
indicates that the additional presence of FII:G20210A increases
the penetrance of thrombotic disease in patients carrying
FV:G1691A. The ﬁndings conﬁrm and extend those reported
in several previous reports, which also described an enhanced
risk of VTE in heterozygotes for FV:G1691A when associated
with FII:G20210A [17,30–33]. The data from our study and the
literature support the importance of the FII:G20210A variant
as a common manifesting risk factor for VT in carriers of the
FV:G1691A mutant.
Between 5 and 20% of unselected Caucasians are homozy-
gous for a C ﬁ T substitution at nucleotide 677 within the
MTHFRgene [34,35]. In the present study, a similar prevalence
Table 5 Coinheritance of factor (F)II:G20210A and MTHFR:C677T in symptomatic homozygous factor (F)V:G1691A carriers
Homozygous
FV:G1691A
Ref.
group B
OR
(95% CI)
Subjects, n 111 177
Median age, years (range) 40 (18–84) 36 (19–84)
FII:G20210A 13 (11.7%) 5 (2.8%) 4.6 (1.6, 13.2)
Homozygous MTHFR:C677T 19 (17.1%) 25 (14.1%) 1.3 (0.7, 2.4)
None of the subjects had homozygous MTHFR:C677T combined with FII:G20210A, none was homozygous for the FII:G20210A variation.
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of the homozygous MTHFR:C677T genotype in the patients
who had suffered VTE and in healthy controls was found. We
therefore conclude that homozygosity of the MTHFR:C677T
allele itself does not contribute to the development of VTE in
FV:G1691A homozygotes, a conclusion similar to those of
several studies of mainly FV:G1691A heterozygotes [35–37],
and that routine investigation for this mutation is not justiﬁed.
These results are in contradiction to some other studies, in
which homozygosity for MTHFR:C677T was identiﬁed as a
signiﬁcant risk factor for VT when coinherited with the
heterozygous FV:G1691A mutation [34,38]. The contradictory
observations may reﬂect different inﬂuences of various other
predisposing factors.
Since data were collected retrospectively and were mainly
basedon informationgivenbythepatient,a recall biascannotbe
excluded.Thismayhaveaffectedboth the rateof reporting as its
accuracy. Moreover, fatal cases were not included. Since life
expectancy does not seemmuch reduced by thrombophilia [39],
this will not have introduced major bias. Obviously, the
proportion of symptomatic individuals in this cohort does not
represent the true distribution, since individuals were mostly
selected because of thrombosis. This implies that the risks and
age-at-onset presented here are likely to be overestimates.
Therefore, we have not presented direct risk estimates for FV
Leiden carriership, either as absolute rates or in a comparison
with population controls. However, with regard to collection of
data on peri- and postoperative thrombosis, as well as OC use,
the evaluation of patients and controls was similar, and data
pertaining to this period preceded the diagnosis or the throm-
botic event.Therefore, it seems reasonable to expectonly limited
bias in the evaluation of these factors. Similarly, the preferential
inclusion of thrombosis patients does not affect the analysis of
effect modiﬁcation by other genetic factors (FII:G20210A,
MTHFR:C677T), since their prevalence in asymptomatic
carriers can be estimated via the population controls.
In conclusion, our study of a large cohort of homozygous
FV:G1691A carriers supports the concept of thrombophilia as
a multifactorial disorder. In the majority of symptomatic
patients an additional genetic or environmental risk factor was
present at ﬁrst thrombotic onset. The identiﬁcation of homo-
zygous individuals may contribute to the prevention of VTE
episodes. By investigation of siblings of homozygous patients
individuals at high risk of thrombosis can be identiﬁed. The
knowledge of coexisting factors predisposing to VTE is useful
for medical advice on primary and secondary prophylaxis in
individuals homozygous for the FV:G1691A mutation.
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